Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181008 | 0.83 | HDAC3 (0.42) | FOLH1ALDH1A1HPGDHDAC3HDAC4 | |
| SCHEMBL180974 | 0.78 | HDAC3 (0.48) | FOLH1ALDH1A1HPGDHDAC3HDAC4 | |
| SCHEMBL181071 | 0.76 | FOLH1 (0.37) | FOLH1ALDH1A1HPGDLMNATP53 | |
| SCHEMBL8530125 | 0.69 | ALDH1A1 (0.51) | FOLH1ALDH1A1HPGDHDAC3HDAC4 | |
| SCHEMBL4335255 | 0.68 | FOLH1 (0.43) | FOLH1ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL180930 | 0.68 | TDP1 (0.33) | ALDH1A1HPGDHDAC3HDAC4HDAC1 | |
| SCHEMBL2329303 | 0.67 | TDP1 (0.37) | ALDH1A1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3067420 | 0.66 | HDAC3 (0.40) | FOLH1ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL1270952 | 0.66 | PLG (0.47) | ALDH1A1HPGDHDAC3HDAC4HDAC1 | |
| SCHEMBL13194872 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006499-B2 | Una amidites and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240182561-A1 | CALCIUM VOLTAGE-GATED CHANNEL AUXILIARY SUBUNIT GAMMA 1 (CACNG1) BINDING PROTEINS AND CACNG1-MEDIATED DELIVERY TO SKELETAL MUSCLE | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11999955-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240173426-A1 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | REGENERON PHARMACEUTICALS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2024107765-A2 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | REGENERON PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240158512-A1 | ANTI-GAL3 ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF | TRUEBINDING, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024098002-A1 | CALCIUM VOLTAGE-GATED CHANNEL AUXILIARY SUBUNIT GAMMA 1 (CACNG1) BINDING PROTEINS AND CACNG1-MEDIATED DELIVERY TO SKELETAL MUSCLE | REGENERON PHARMACEUTICALS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240132610-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240124600-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20240082359-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20190314455-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | SANOFI (FR) | 2019-10-17 | — | — | US | disclosed |
| US-20190298847-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2019-10-03 | — | — | US | disclosed |
| US-10335496-B2 | ROR1 antibody immunoconjugates | VelosBio Inc. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190192681-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20180369400-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES, INC. | 2018-12-27 | — | — | US | disclosed |
| US-20180369406-A1 | ROR1 Antibody Immunoconjugates | VelosBio Inc. (US) | 2018-12-27 | — | — | US | disclosed |
| US-20180371102-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2018-12-27 | — | — | US | disclosed |
| US-20170281795-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-8936910-B2 | Method for selective oligonucleotide modification | ANTISENSE PHARMA GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-20130172238-A1 | METHOD FOR SELECTIVE OLIGONUCLEOTIDE MODIFICATION | ANTISENSE PHARMA GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124600-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MYOF, MTPN, PYGM | FOLH1 742/4885ALDH1A1 3512/4885HPGD 1429/4885 |
| US-20170281795-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | FOLH1 266/4885ALDH1A1 4316/4885HPGD 4185/4885 |
| US-20180371102-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | FOLH1 266/4885ALDH1A1 4316/4885HPGD 4185/4885 |
| US-20180369406-A1 | ROR1 Antibody Immunoconjugates | RORA, RORB, RORC | FOLH1 188/4885ALDH1A1 140/4885HPGD 4273/4885 |
| US-20240082359-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | FOLH1 169/4885ALDH1A1 1034/4885HPGD 504/4885 |
| US-20190314455-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | FOLH1 169/4885ALDH1A1 1034/4885HPGD 504/4885 |
| US-20180369400-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | NSUN2, UPF1, SNRPE | FOLH1 1948/4885ALDH1A1 4451/4885HPGD 4214/4885 |
| US-10335496-B2 | ROR1 antibody immunoconjugates | RORA, RORB, RORC | FOLH1 188/4885ALDH1A1 140/4885HPGD 4273/4885 |
| US-20240182561-A1 | CALCIUM VOLTAGE-GATED CHANNEL AUXILIARY SUBUNIT GAMMA 1 (CACNG1) BINDING PROTEINS AND CACNG1-MEDIATED DELIVERY TO SKELETAL MUSCLE | CACNG1, CACNG3, CACNG2 | FOLH1 1548/4885ALDH1A1 3569/4885HPGD 3905/4885 |
| US-20240173426-A1 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | FGFR3, FGFR2, FGFR1 | FOLH1 187/4885ALDH1A1 4031/4885HPGD 4396/4885 |
| US-20190298847-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | MTPN, MYOF, TNNC1 | FOLH1 3761/4885ALDH1A1 4206/4885HPGD 2847/4885 |
| US-20190192681-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | FOLH1 281/4885ALDH1A1 4367/4885HPGD 4205/4885 |
| US-20130172238-A1 | METHOD FOR SELECTIVE OLIGONUCLEOTIDE MODIFICATION | TLR3, POLRMT, POLI | FOLH1 2602/4885ALDH1A1 3790/4885HPGD 4512/4885 |
| US-20240132610-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MYOF, MTPN, PYGM | FOLH1 742/4885ALDH1A1 3512/4885HPGD 1429/4885 |
| US-12006499-B2 | Una amidites and uses thereof | NCL, PNP, NASP | FOLH1 1347/4885ALDH1A1 3878/4885HPGD 2348/4885 |
| US-11999955-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | MTPN, MYOF, CPT1B | FOLH1 1354/4885ALDH1A1 3424/4885HPGD 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.